HIMS
Hims & Hers Health, Inc.

Hims & Hers Health, Inc.HIMS

Healthcare · Drug Manufacturers - Specialty & Generic
26.00USD
+8.06%
Nov 08, 2026
HIMS overview ready
Direct-to-consumer telehealth platform enabling obesity treatment access
Direct-to-consumer telehealth platform that connects patients with licensed providers and facilitates ongoing obesity-treatment access, including FDA-approved GLP-1 options alongside digital care and fulfillment workflows.
Theme not measured
No economic group is assigned yet.
Price trend is broken
Longer-term context reads trend under pressure, with a near-term setup of distribution pressure.
The tactical setup reads distribution pressure, but the weekly structure is broken.
Demanding valuation
The price embeds expectations that run ahead of the cash the business currently produces.
Unremarkable fundamentals
Primary risk
Regulatory changes affecting telehealth and prescription drug delivery.
Market Nov 6Filing Jun 30Price action Nov 7Research Aug 7

Conviction Level

Theme Momentum has no canonical measurement for this company — a research-profile dimension, not an input to this score.

PriceAction5.4BusinessPerformance5.0BusinessQuality4.2Valuation1.3ThemeMomentum—Mixed — Revenue growth has accelerated, rising from +3.8% to +38% year over year. Earnings turned negative: a diluted loss of -$0.37 against EPS of $0.17 a year earlier. — From filed financial statements. Describes the recent trajectory of the business, not the stock. 20 of the 100 Conviction points.

Conviction uses Price Action, Business Performance, Business Quality, Valuation. Theme Momentum is research context, not an input.

Theme momentumPrimary theme · group context, not entry timing
No economic group yet — pending research
Price
Loading price history…

Price Action

Price trend is broken
Longer-term context reads trend under pressure, with a near-term setup of distribution pressure.
The tactical setup reads distribution pressure, but the weekly structure is broken.
EntryConstructive

Structure is constructive on both timeframes without excessive extension — a reasonable entry location.

Key Financials

Market Cap
$6.0B
Avg Volume (60D)
10.0M
60 sessions
Revenue Growth YoY
+59.0%
FY2025 vs FY2024
Gross Margin
+68.4%
Trailing twelve months
Operating Margin
-6.0%
Trailing twelve months
Free Cash Flow Yield
+1.0%
Distance from 200DMA
-3.4%
Next Earnings
2026-11-09
P/E
N/M
EV / Sales
2.5x
Market metrics as of Nov 6, 2026
Financial results for the period ended Jun 30, 2026
Filed balance-sheet data as of Jun 30, 2026

Business Performance

Mixed

Revenue growth has accelerated, rising from +3.8% to +38% year over year. Earnings turned negative: a diluted loss of -$0.37 against EPS of $0.17 a year earlier.

Latest reported: Q2 FY2026, ended Jun 30
Revenue growthAccelerating
+38%
$753M in Q2 FY2026 · YoY
YoY growth, last 4 quarters
  1. +49%
  2. +28%
  3. +3.8%
  4. +38%
Earnings growthTurned to a loss
-$0.37
Diluted EPS -$0.37 vs $0.17 a year earlier · GAAP
Diluted EPS YoY (GAAP), last 4 quarters
  1. -81%
  2. -27%
  3. n/a
  4. n/a
Operating marginContracting
-12.9%
-17.8 pp YoY · gross margin 63.8% (-12.6 pp)

Business Quality

4.2 / 10

How well the business earns on its assets, converts earnings to cash and funds itself — read from its SEC filings.

Fundamentals & Valuation

Two of the three valuation perspectives say expensive; own history is the dissenting view.
Hims & Hers Health, Inc. has an Expensive valuation stance because the price embeds expectations that run ahead of the cash the business currently produces. It trades at 2.5x revenue, which requires sustained delivery to be justified.

What changed

  • HIMS fell 8.8% in one session
    HIMS closed -8.8% while the broad market was close to flat (-0.5%).
    2026-11-02
  • HIMS rose 10.2% in one session
    HIMS closed +10.2% while the broad market was close to flat (+0.6%).
    2026-10-09

Company Research

Thesis
Direct-to-consumer telehealth platform that connects patients with licensed providers and facilitates ongoing obesity-treatment access, including FDA-approved GLP-1 options alongside digital care and fulfillment workflows.
Opportunity
Moderate opportunity
Consumer demand and healthcare-system efforts to widen convenient, affordable access to obesity medicines and longitudinal metabolic-care support through digital care platforms.
Key risk
Regulatory changes affecting telehealth and prescription drug delivery.

Economic classification

Loading the economic classification…

Business & Markets

Healthcare · Drug Manufacturers - Specialty & Generic
What they do

Hims & Hers Health, Inc. operates a consumer-first digital health platform that connects customers to licensed healthcare professionals and offers prescription and non-prescription health and wellness products through its websites and mobile app across multiple countries.

How it earns

The company generates revenue primarily through direct-to-consumer transactional sales of health and wellness products and services.

Products & services
Prescription medications including obesity treatments
Over-the-counter drugs and devices
Cosmetics
Supplements
Telehealth consultations
Customers & end markets
Individual consumers seeking convenient healthcare access
Patients requiring metabolic and obesity care
Market position

A challenger in the digital telehealth and specialty drug delivery space focused on metabolic and wellness care.

Demand drivers
Low cyclicality

Demand for healthcare and prescription medications is relatively stable and less sensitive to economic cycles.

Related companies

Finding other covered companies in the same part of this story…